Neuroendocrine Tumors (NETs) – Global Drug Forecast and Market Analysis to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The global neuroendocrine tumors drug market was valued at $3.11 billion in 2020 and is projected to grow at a CAGR of more than 0.5% during the forecast period 2021-2030. The introduction of five new pipeline agents and label expansions or entry into new markets for currently approved agents are key drivers of this market growth. However, the market will largely stagnate during the forecast period due to patent expiries impacting most of the standard of care. The US was the leading market in 2020, claiming more than 60% of global sales followed by China and France.

Global neuroendocrine tumors drug market overview

Global neuroendocrine tumors drug market overview

For more insights on this report, download a free report sample

What are the market dynamics in the global neuroendocrine tumors (NETs) drug market?

Despite NETs being considered rare malignancies, there has been a consistent industrial interest and therefore investment in the field. The blockbuster combined sales of SSAs suggest that an agent which offers a meaningful improvement in patient outcomes can certainly lead to highly satisfactory commercial success. By 2021, the R&D focus on NETs has expanded to include numerous targeted therapies, PRRT, and other novel ways to improve the current mechanisms of action (MOAs) targeting somatostatin receptors (SSTRs). There has been a shift from researching me-too drugs to researching compounds with the same MOA offering key improvements over currently marketed products, which are expected to be better in one or more attributes.

Due to the heterogeneity of the disease, there are distinct patient populations with different unmet needs, in which any new agent or modality could potentially carve its own space. For instance, PRRT has already been very successful, but if a new way to target the SSTR upon progression with PRRT emerges, that would capture the majority of the third/fourth line sales in this indication. There has been a shift from researching me-too drugs to researching compounds with the same mechanism of action as other marketed products but which are expected to be better in one or more attributes.

The treatment of neuroendocrine tumors is associated with a medium level of unmet need, medium because there is not a definitive curative therapy for advanced disease, while at the same time most patients present with slow-growing disease and do have a number of drug options available that can extend survival over multiple lines of therapy. From January 2011 to December 2020, deal-making in the NET space has not followed any specific patterns. Mergers & acquisitions, as well as strategic alliances, were well represented, albeit not as common or frequent as seen in other cancer indications. Agreements to exercise co-marketing rights for individual drugs are notably absent from the NET landscape.

Which are the major players in the global neuroendocrine tumors (NETs) drug market?

The current major players in the neuroendocrine tumor space are Novartis, Ipsen, Hutchmed, and Pfizer, and current players with a smaller market share are Merck & Co, Roche, and Lantheus Holdings. The market leader by a significant margin is Novartis, with a drug portfolio that spans every patient population in NETs and controls approximately 51% of the NET market, according to GlobalData’s estimates.

Global neuroendocrine tumors drug market, by key players

Global neuroendocrine tumors drug market, by key players

To know more about key players, download a free report sample

Market report scope

Global Market (8MM) 2020 $3.11 billion
Growth Rate CAGR of <1% (2030)
Key Players Blueprint Medicines, Bristol Myers Squibb, Camurus AB, Exelixis Inc, Hutchmed, Ipsen Pharma, ITM Isotopen Technologien Munchen, Merck & Co, Novartis, Pfizer, Progenics Pharmaceuticals, Roche, and Shanghai Junshi Bioscience

This report provides a comprehensive analysis of Neuroendocrine Tumors (NETs) – Global Drug

  • Tumors including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Neuroendocrine Tumors market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Neuroendocrine Tumor therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II – III).
  • Analysis of the current and future market competition in the global Neuroendocrine Tumor therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Neuroendocrine Tumor therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine Tumor market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Neuroendocrine Tumor therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Blueprint Medicines
Bristol Myers Squibb
Camurus AB
Exelixis Inc
Hutchmed
Ipsen Pharma
ITM Isotopen Technologien Munchen
Merck & Co
Novartis
Pfizer
Progenics Pharmaceuticals
Roche
Shanghai Junshi Bioscience

Table of Contents

Table of Contents

| About GlobalData

1 Neuroendocrine Tumors: Executive Summary

1.1 The Neuroendocrine Tumor Market Will Grow at a

0.9% CAGR During 2020-2030

1.2 Key Improvements in Existing Mechanisms of Action Form the Dominant Corporate and R&D Strategy in Neuroendocrine Tumors

1.3 Matching a Patient with the Most Appropriate Therapy Remains the Most Important Unmet Need in Neuroendocrine Tumors

1.4 Low Level of Innovation Across the Late-Stage Pipeline to Introduce Minimal Disruption in the Treatment Landscape

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods: Population – 8MM

4.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs – 8MM

4.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Type

4.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Stage and Type

4.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Grade and Differentiation

4.4.7 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of NETs

4.5 Epidemiological Forecast for NETs, 2020-2030

4.5.1 Diagnosed Incident Cases of NETs

4.5.2 Age-Specific Diagnosed Incident Cases of NETs

4.5.3 Sex-Specific Diagnosed Incident Cases of NETs

4.5.4 Diagnosed Incident Cases of NETs by Type

4.5.5 Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis

4.5.6 Diagnosed Incident Cases of NETs by Grade and Differentiation

4.5.7 Five-Year Diagnosed Prevalent Cases of NETs

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

5.2.1 Diagnosis

5.2.2 Surgical management

5.2.3 Systemic therapy

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Predictive Biomarkers to Match a Patient with the Most Appropriate Therapy

7.3 Safer Targeted Therapies for Low-Grade Tumors and More Efficacious Therapies for High-Grade Tumors

7.4 More Informed Use of Currently Available Drugs

7.5 Well-Tolerated Agents for SSTR Negative Tumors

8 R&D Strategies

8.1 Overview

8.1.1 Enhancing the Validated Strategy of PRRT

8.1.2 Novel Ways to Target SSTRs

8.1.3 Replacing Older Targeted Therapies with Next Generation Kinase Inhibitors and Immune Checkpoint Inhibitors

8.2 Clinical Trials Design

8.2.1 Endpoints More Suitable to NETs

8.2.2 Academically Sponsored and Collaborative Trials

8.2.3 Clinical Trial Challenges

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 China

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.3.2 Diagnosed Patients

13.3.3 Percent Drug-Treated Patients

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

13.7 Contact Us

Table

Table 1: Neuroendocrine tumors: Key Metrics in the 8MM

Table 2: Grade and Proliferation Segmentation in Neuroendocrine Tumors

Table 3: Risk Factors and Comorbidities for NETs

Table 4: Treatment Guidelines for NETs

Table 5: Top 10 Deals by Value, 2011-2020

Table 6: NET Market – Global Drivers and Barriers, 2020-2030

Table 7: Key Events Impacting Sales for NETs in the US, 2020-2030

Table 8: NET Market – Drivers and Barriers in the US, 2020-2030

Table 9: Key Events Impacting Sales for NETs in the 5EU, 2020-2030

Table 10: NET Market – Drivers and Barriers in the 5EU, 2020-2030

Table 11: Key Events Impacting Sales for NETs in Japan, 2020-2030

Table 12: NET Market – Drivers and Barriers in Japan, 2020-2030

Table 13: Key Events Impacting Sales for NETs in China, 2020-2030

Table 14: NET Market – Drivers and Barriers in China, 2020-2030

Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for NETs in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in NETs During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of NETs During the Forecast Period

Figure 4: Key Therapeutic Targets in Neuroendocrine Tumors

Figure 5: 8MM, Diagnosed Incidence of NETs, Men, Cases per 100,000 Population, All Ages, 2010 and 2020

Figure 6: 8MM, Diagnosed Incidence of NETs, Women, Cases per 100,000 Population, All Ages, 2010 and 2020

Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of NETs

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Type

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Stage at Diagnosis, by Type

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Grade and Differentiation, by Type

Figure 11: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of NETs

Figure 12: 8MM, Diagnosed Incident Cases of NETs, N, Both Sexes, All Ages, 2020

Figure 13: 8MM, Diagnosed Incident Cases of NETs by Age, N, Both Sexes, 2020

Figure 14: 8MM, Diagnosed Incident Cases of NETs by Sex, N, All Ages, 2020

Figure 15: 8MM, Diagnosed Incident Cases of NETs by Type, N, Both Sexes, 2020

Figure 16: 8MM, Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis, N, Both Sexes, All Ages, 2020

Figure 17: 8MM, Diagnosed Incident Cases of NETs by Grade and Differentiation, N, Both Sexes, All Ages, 2020

Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of NETs, N, Both Sexes, All Ages, 2020

Figure 19: Treatment Algorithm for NETs

Figure 20: Unmet Needs and Opportunities in Neuroendocrine Tumors

Figure 21: Overview of the Development Pipeline in NETs

Figure 22: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for NETs in the 8MM During the Forecast Period

Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against Afinitor and Lutathera

Figure 24: Analysis of the Company Portfolio Gap in NETs During the Forecast Period

Figure 25: Global (8MM) Sales Forecast by Country for NETs in 2020 and 2030

Figure 26: Sales Forecast by Class for NETs in the US in 2020 and 2030

Figure 27: Sales Forecast by Class for NETs in the 5EU in 2020 and 2030

Figure 28: Sales Forecast by Class for NETs in Japan in 2020 and 2030

Figure 29: Sales Forecast by Class for Neuroendocrine tumors in China in 2020 and 2030

Frequently asked questions

Neuroendocrine Tumors (NETs) – Global Drug Forecast and Market Analysis to 2030 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Neuroendocrine Tumors (NETs) – Global Drug Forecast and Market Analysis to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Neuroendocrine Tumors (NETs) – Global Drug Forecast and Market Analysis to 2030 in real time.

  • Access a live Neuroendocrine Tumors (NETs) – Global Drug Forecast and Market Analysis to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.